Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Xencor, Inc. (XNCR) PT Lowered to $31 at RBC Capital
June 14, 2024 6:25 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Xencor, Inc. (NASDAQ: XNCR) to $31.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "This morning XNCR disclosed the company has regained plamotamab (CD20 x CD3) as partner Janssen will terminate its... More
